Brief Description:
First-in-Human safety and tolerability study in adult participants with confirmed PKD1 mutation-associated ADPKD. The anticipated number of participants across 3 Part B (SAD – ADPKD) cohorts is approximately 18 participants. On Day 1, each participant will receive PYC-003 as a single IV infusion.
Type of research:
Clinical Trial
Your time commitment:
Other
Consumers re-imbursed?
Expenses covered
Who are researchers looking for?
Person with early stage kidney disease
Contact for more info:
Email: jessica.stevenson@pyctx.com
Phone: +61448041918
